Asia Pacific
Refine Search
Biotechnology
Japanese drugmaker Takeda has launched Fruzaqla (fruquintinib) in its home country. 22 November 2024
Biotechnology
Chinese biopharma CStone Pharmaceuticals has announced a strategic commercial collaboration with Pharmalink Store, a prominent pharmaceutical company based in the United Arab Emirates (UAE). 22 November 2024
Biotechnology
Zhongshan-based biopharma company Akeso will await the verdict of the Chinese medicines regulator on a penpulimab-based combo therapy. 22 November 2024
Pharmaceutical
Shanghai-based Zai Lab and New York’s Pfizer are to work together on the commercialization of Xacduro (sulbactam-durlobactam) in China. 22 November 2024
Biotechnology
Hong Kong-based Sino Biopharm has signed an equity investment and strategic collaboration agreement with LaNova Medicines, advancing its oncology focus. 22 November 2024
Pharmaceutical
Japanese drugmaker Eisai has announced that the amyotrophic lateral sclerosis (ALS) treatment Rozebalamin for Injection (mecobalamin) has been launched in Japan as a treatment for slowing progression of functional impairment in amyotrophic lateral sclerosis. 21 November 2024
Biotechnology
San Diego-based Kura Oncology and Japan’s Kyowa Kirin have entered into a global strategic collaboration to develop and commercialize ziftomenib. 21 November 2024
Pharmaceutical
Shanghai-based Leading Tac Pharmaceutical has announced the successful completion of a series A financing round, raising over 100 million yuan ($14 million). 21 November 2024
Pharmaceutical
Ascentage Pharma will see its investigational BCL-2 selective inhibitor, lisaftoclax, assessed under China’s Priority Review scheme. 20 November 2024
Pharmaceutical
California, USA-based biotech Cytokinetics saw its shares fall as much as 4% to $9.67 yesterday, after it announced a deal with Germany’ Bayer. 20 November 2024
Biotechnology
Californian oncology-focused biotech Avenzo Therapeutics has announced a pair of important updates. 19 November 2024
Pharmaceutical
Big pharmas are not deterred by China’s increasingly complex business environment. Instead, they are changing strategies to minimize risks while continuing to benefit from China, said speakers at ChinaTrials held last week in Shanghai. 18 November 2024
Biosimilars
Following US approval in May this year, South Korea’s Samsung Bioepis and US biotech Biogen have now won approval from the European Commission (EC) for their Opuviz 40mg/mL solution for injection in a vial, a biosimilar referencing Regeneron and Bayer’s Eylea (aflibercept). 18 November 2024
Biotechnology
Shanghai-based Junshi Biosciences has received UK regulatory approval for Loqtorzi (toripalimab) in nasopharyngeal carcinoma (NPC) and esophageal squamous cell carcinoma (ESCC). 18 November 2024
Biotechnology
Chinese biotech Keymed Biosciences has entered an exclusive licensing agreement with Platina Medicines for its bispecific antibody candidate, CM336. 18 November 2024
Pharmaceutical
In yet another sign of the mounting interest in radiopharmaceuticals, Tongrui Biopharma, a Chinese innovator in this area, has announced the completion of a $100 million series A+ financing round. 18 November 2024
Biotechnology
Shanghai-based biopharma Zai Lab has announced the pricing of its underwritten public offering at $25.50 per share, aiming to raise around $200 million. 15 November 2024
Biosimilars
South Korean biosimilars company Celltrion today announced its acquisition of iQone Healthcare Switzerland a specialty pharmaceutical company focused on distribution, sales, and marketing in Switzerland. 15 November 2024
Biotechnology
Merck & Co has entered into an exclusive global license to develop, manufacture and commercialize LM-299 from China-based clinical-stage biotech LaNova Medicines, bringing the US pharma giant into the newly attractive PD-1/VEGF bispecific antibody space. 15 November 2024
Biotechnology
Japanese drugmaker Nippon Shinyaku and USA-based Atsena Therapeutics have entered into an exclusive license agreement for the commercialization of ATSN-101 in the USA and Japan for advancing Atsena’s first- in-class, investigational gene therapy ATSN-101 for Leber congenital amaurosis caused by biallelic mutations in GUCY2D (LCA1). 13 November 2024
Biotechnology
The life sciences division of tech major NEC Corporation has bought immuno-oncology assets from Swiss-German biotech Vaximm, for an undisclosed amount. 8 March 2022
Biotechnology
Japanese drug major Chugai Pharmaceutical Chugai has filed a regulatory application with the Ministry of Health, Labor and Welfare (MHLW), for approval of an anti-cancer agent/humanized anti-CD20 monoclonal antibody Gazyva (obinutuzumab), intravenous infusion 1000mg (genetical recombination)] for the treatment of chronic lymphocytic leukemia (CLL). 7 March 2022
Biotechnology
Japanese pharma major Shionogi today announced the interim report of a Phase II/III additional dose clinical trial of S-268019, a preventive vaccine for COVID-19. 4 March 2022
Biotechnology
Setting aside trouble gaining market access for the newly-approved Aduhelm (aducanumab), Eisai and Biogen continue to pursue early registration of their next-generation Alzheimer’s med. 4 March 2022
Biotechnology
Danish allergy immunotherapy specialist ALK Abello said today that it expects to submit a registration application in China for its house dust mite (HDM) sublingual allergy immunotherapy (SLIT) tablet already in 2022. 3 March 2022
Pharmaceutical
Japanese companies JCR Pharmaceuticals and Sumitomo Dainippon Pharma have agreed a marketing alliance for the Fabry disease treatment agalsidase beta BS IV infusion at 5mg and 35mg in Japan. 2 March 2022
Generics
Taiwanese generics and biosimilar drugmaker Lotus Pharmaceutical has received approval for its abbreviated new drug application (ANDA) in the Philippines for its generic versions of Bristol Myers Squibb’s Revlimid (lenalidomide) and AstraZeneca’s lung cancer drug Iressa (gefitinib). 2 March 2022
Pharmaceutical
Germany’s Heidelberg Pharma has gained a potentially significant route into the Chinese market via a blockbuster licensing deal. 1 March 2022
Biotechnology
South Korea’s GC Pharma saw its shares fall 6.2% to 182,000 won, after it revealed it has received a Complete Response Letter (CRL) from the US Food and Drug Administration in response to its Biologics License Application (BLA) for Alyglo (immune globulin intravenous (human), 10% liquid). 28 February 2022
Biotechnology
GlobalData has taken a look at the acute myeloid leukemia (AML) treatment landscape in China. 25 February 2022
Biotechnology
Rare diseases specialist Swedish Orphan Biovitrum, also known as Sobi, today announced that the Center for Drug Evaluation (CDE) has recommended approval of Gamifant (emapalumab) to the National Medical Products Administration of China (NMPA). 25 February 2022
Pharmaceutical
The first home-grown coronavirus pill in Japan has been submitted to the medicines regulator for early approval. 25 February 2022
Biotechnology
The World Health Organization (WHO), the Republic of Korea and the WHO Academy have established a global biomanufacturing training hub that will serve all low- and middle-income countries wishing to produce biologicals, such as vaccines, insulin, monoclonal antibodies and cancer treatments. 24 February 2022
Biotechnology
Japanese drugmaker Ono Pharmaceutical says that its Taiwanese subsidiary has received an approval of Velexbru (tirabrutinib hydrochloride) tablet 80mg, a Bruton’s tyrosine kinase (BTK) inhibitor, from the Taiwan Food and Drug Administration (TFDA) for the treatment of adult patients with recurrent or refractory B-cell primary central nervous system lymphoma. 21 February 2022
Biosimilars
South Korea’s Celltrion Healthcare announced new data sets on the SC formulation of infliximab, Remsima (CT-P13) in IBD, at the European Crohn’s and Colitis Organization (ECCO) virtual congress 2022. 21 February 2022
Biotechnology
Chinese biopharma firm Innovent Biologics has announced that its experimental anti-PCSK9 antibody, named IBI306, has come up trumps in two Phase III trials in China. 18 February 2022
Biotechnology
China-based biotech BeiGene today announced that BeiGene’s BTK inhibitor Brukinsa (zanubrutinib) has received approval from Swissmedic for the treatment of adult patients with Waldenström’s macroglobulinemia (WM). 17 February 2022
Biotechnology
China's National Medical Products Administration (NMPA) has approved Benlysta (belimumab) for the treatment of adult patients with active lupus nephritis (LN) who are receiving standard of care. 10 February 2022
Pharmaceutical
Since the early days of the pandemic, a number of developers have pursued the concept of using a nasal spray to administer anti-virals for treatment and prevention of coronavirus. 9 February 2022
Pharmaceutical
The single shot variant of Russia’s coronavirus vaccine, Sputnik Light, has been approved for use in India. 7 February 2022
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze